- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Kalveer Flora, MPharm: Coordinating With Providers on Biosimilar Switching
Kalveer Flora, MPharm, London North West University Healthcare National Health Service (NHS) Trust, discusses how she coordinates with providers on biosimilar switching programs.
Transcript
In order to maintain sustainability and make sure that the switch goes well, what I like to do is organize regular catch-ups and touch base just to see how the homecare providers are doing in terms of switching.
What we do is, I usually switch patients in batches, so patients who have come to the clinic and have been told that they’ll be changing. I communicate this information to the homecare providers so that they know which patients they will be delivering the biosimilar to.
It’s important that homecare providers are aware, and also that they have enough medicines, because the last thing that I want is to switch a patient and there to be a problem with procuring the biosimilar for them. So it’s just really about organization and communication.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
